Pembrolizumab Wins FDA Approval in Operable Lung Cancer
(MedPage Today) -- The FDA approved pembrolizumab (Keytruda) on Monday in combination with platinum-based chemotherapy for the perioperative treatment of resectable non-small cell lung cancer (NSCLC).
Approval was based on improved event-free...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lung Cancer | Non-Small Cell Lung Cancer